Detection of circulating genetically abnormal cells in peripheral blood for early diagnosis of non‐small cell lung cancer
Autor: | Dongsheng Yue, Zhou Yanling, Chen Chen, Jing Ma, Xianjun Fan, Changli Wang, Yue Li, Zhenfa Zhang, Weiran Liu, Chenguang Li, Yansong Huo, Bin Zhang, Shu-Yu He, Jun-Cheng Zhang, Hua Zhang, Dongjiang Tang, Ye Xin, Yu-Chen Ma |
---|---|
Rok vydání: | 2020 |
Předmět: |
Male
0301 basic medicine Pulmonary and Respiratory Medicine Oncology medicine.medical_specialty Lung Neoplasms lcsh:RC254-282 03 medical and health sciences 0302 clinical medicine Carcinoma Non-Small-Cell Lung Internal medicine Biomarkers Tumor medicine Humans Prospective Studies cardiovascular diseases Stage (cooking) early detection Lung cancer Prospective cohort study non‐small‐cell lung cancer Early Detection of Cancer medicine.diagnostic_test Receiver operating characteristic business.industry nutritional and metabolic diseases Original Articles Biomarker General Medicine Middle Aged lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens medicine.disease Peripheral blood respiratory tract diseases 030104 developmental biology small nodules 030220 oncology & carcinogenesis population characteristics Biomarker (medicine) Female Original Article circulating genetically abnormal cells Non small cell business Fluorescence in situ hybridization |
Zdroj: | Thoracic Cancer Thoracic Cancer, Vol 11, Iss 11, Pp 3234-3242 (2020) |
ISSN: | 1759-7714 1759-7706 |
Popis: | Background Circulating genetically abnormal cells (CACs) with specific chromosome variations have been confirmed to be present in non‐small cell lung cancer (NSCLC). However, the diagnostic performance of CAC detection remains unclear. This study aimed to evaluate the potential clinical application of the CAC test for the early diagnosis of NSCLC. Methods In this prospective study, a total of 339 participants (261 lung cancer patients and 78 healthy volunteers) were enrolled. An antigen‐independent fluorescence in situ hybridization was used to enumerate the number of CACs in peripheral blood. Results Patients with early‐stage NSCLC were found to have a significantly higher number of CACs than those of healthy participants (1.34 vs. 0.19; P Workflow of circulating genetically abnormal cells enumeration. Circulating genetically abnormal cell detection in early stage non‐small‐cell lung cancer was feasible. Circulating genetically abnormal cell test has good stability and adaptability for different patient populations. Circulating genetically abnormal cells could be used as a promising noninvasive biomarker for the early diagnosis of NSCLC. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |